Drugmakers Roche
and Trimeris on Monday filed for Food and Drug
Administration approval of the Biojector 2000, a needle-free
injection system to administer their HIV fusion
inhibitor Fuzeon. The Biojector 2000, developed by
Bioject Medical Technologies, works by using a carbon
dioxide cartridge to power an intense spray of medication
that penetrates the skin. The device has been
available since 1996 and has been approved to
administer several other medications that require
subcutaneous or intramuscular administration. The drug
companies say they expect a decision by the FDA later
this year.
